MTNB Share Price | Matinas BioPharma Holdings, Inc. Stock Analysis & Recommendation

Q: How big is Matinas BioPharma Holdings, Inc.?

Market Cap: As of Jun 18, Matinas BioPharma Holdings, Inc. has a market capitalization of 4.65 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Matinas BioPharma reported net sales of 0.00 million and a net profit of -20.09 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7.59 million and total assets of 12.64 million.

Q: What does Matinas BioPharma Holdings, Inc. do?

Overview: Matinas BioPharma Holdings, Inc. is a development stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 4.65 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -256.46% Price to Book: 0.74Contact Details: Address: SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER NJ : 7921 Tel: ['1 908 4431860', '1 415 7224563'] Fax: 1 302 6365454 Website: https://www.matinasbiopharma.com/

Q: Is Matinas BioPharma Holdings, Inc. overvalued or undervalued?

As of 9 May 2024, Matinas BioPharma Holdings, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its significant financial challenges, including a price-to-book value of 0.75 and an EV to EBITDA ratio of 0.09, which indicate poor financial health and operational inefficiency. The return on equity (ROE) is alarmingly low at -256.46%, highlighting the company's struggles to generate profit from its equity base.In comparison to its peers, Matinas BioPharma's valuation metrics are concerning. For instance, ASP Isotopes, Inc. has a P/E ratio of -24.0140, while ARCA biopharma, Inc. shows a P/E of -5.3909, both indicating a similarly distressed financial state. Furthermore, the company's stock has underperformed significantly over the past year, with a return of -88.56% compared to the S&P 500's gain of 10.26%, reinforcing the notion that Matinas BioPharma is overvalued in its current state.

Q: Is Matinas BioPharma Holdings, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Matinas BioPharma Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish while the monthly MACD is mildly bullish, indicating some positive momentum. The weekly RSI is bearish, contrasting with the monthly RSI which is bullish, suggesting mixed signals across time frames. The daily moving averages are bullish, supporting a short-term positive outlook. However, Bollinger Bands show a mildly bullish weekly stance but a bearish monthly stance, adding to the mixed signals. In terms of performance, the stock has a year-to-date return of 239.22%, significantly outperforming the S&P 500's 12.22% during the same period, but it has underperformed over the longer term with a 1-year return of -50.85% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by conflicting indicators and longer-term underperformance.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

840

Shareholding (Sep 2025)

FII

15.30%

Held by 6 FIIs

DII

80.3%

Held by 5 DIIs

Promoter

0.00%

How big is Matinas BioPharma Holdings, Inc.?

22-Jun-2025

As of Jun 18, Matinas BioPharma Holdings, Inc. has a market capitalization of 4.65 million, with net sales of 0.00 million and a net profit of -20.09 million over the latest four quarters. The company reported shareholder's funds of 7.59 million and total assets of 12.64 million as of Dec 24.

View full answer

What does Matinas BioPharma Holdings, Inc. do?

22-Jun-2025

Matinas BioPharma Holdings, Inc. is a micro-cap biopharmaceutical company focused on developing novel pharmaceutical products. As of March 2025, it reported a net loss of $2 million and has a market cap of $4.65 million.

View full answer

Who are in the management team of Matinas BioPharma Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Matinas BioPharma Holdings, Inc. includes Mr. Herbert Conrad (Independent Chairman), Mr. Jerome Jabbour (CEO), Mr. Patrick LePore (Independent Vice Chairman), and several independent directors: Dr. Eric Ende, Ms. Natasha Giordano, Mr. James Scibetta, and Dr. Matthew Wikler. This team combines executive leadership with independent oversight for strategic governance.

View full answer

Is Matinas BioPharma Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2024, Matinas BioPharma Holdings, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to significant financial challenges, including a low return on equity of -256.46% and poor performance compared to peers and the S&P 500.

View full answer

Is Matinas BioPharma Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Matinas BioPharma Holdings, Inc. shows a mildly bullish trend with mixed signals across different time frames, having a year-to-date return of 239.22% but a 1-year return of -50.85%, indicating conflicting indicators and longer-term underperformance.

View full answer

Compare Matinas BioPharma Holdings, Inc. with Similar Stocks

Lumos Pharma, Inc.Cellectar Biosciences, Inc.Qilian International Holding Group Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.72

Return on Equity

-153.13%

Price to Book

0.61

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.61%

6 Months

-70.31%

1 Year

-4.95%

2 Years

-95.9%

3 Years

42.75%

4 Years

-98.69%

5 Years

-98.91%

Matinas BioPharma Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-2.09%

EBIT Growth (5y)

9.84%

EBIT to Interest (avg)

-23.10

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

28.82%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.61

EV to EBIT

0.07

EV to EBITDA

0.08

EV to Capital Employed

-0.38

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-153.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (4.41%)

Foreign Institutions

Held by 6 Foreign Institutions (15.3%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 59.62% vs -205.88% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-1.70",
          "chgp": "11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-5.20",
          "chgp": "59.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -65.62% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.11% vs -9.05% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-22.80",
          "chgp": "15.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.20",
          "val2": "0.60",
          "chgp": "-800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.30",
          "val2": "-22.90",
          "chgp": "-6.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-21,684.30%",
          "chgp": "2,168.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.50

-1.70

11.76%

Interest

0.00

Exceptional Items

0.00

-3.50

100.00%

Consolidate Net Profit

-2.10

-5.20

59.62%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 59.62% vs -205.88% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

1.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-19.20

-22.80

15.79%

Interest

0.00

Exceptional Items

-4.20

0.60

-800.00%

Consolidate Net Profit

-24.30

-22.90

-6.11%

Operating Profit Margin (Excl OI)

0.00%

-21,684.30%

2,168.43%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -65.62% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.11% vs -9.05% in Dec 2023

All Annual Results

Company CV

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

Pharmaceuticals & Biotechnology

Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.

Company Coordinates

Company Details

SUITE 302, 1545 ROUTE 206 SOUTH , BEDMINSTER NJ : 7921

Tel: 1 908 44318601 415 7224563

https://www.matinasbiopharma.com/

Registrar Details